Inhibitors of melanogenesis: a patent review (2009 – 2014)

Bibliography

• Francisco S, Stefania B, Mauro P, et al. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006;19:550-71
   PubMedGoogle Scholar
• Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007;445:843-50
   PubMed Web of Science ®Google Scholar
• Park HY, Kosmadaki M, Yaar M, et al. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009;66:1493-06
   PubMed Web of Science ®Google Scholar
• Costin GE, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 2007;21:976-94
   PubMed Web of Science ®Google Scholar
• Hearing VJ, Körner AM, Pawelek JM. New regulators of melanogenesis are associated with purified tyrosinase isozymes. J Invest Dermatol 1982;79:16-18
   Google Scholar
• Hearing VJ, Jiménez M. Mammalian tyrosinase. The critical regulatory control point in melanocyte pigmentation. Int J Biochem 1987;19:1141-7
   PubMedGoogle Scholar
• Prota G. Progress in the chemistry of melanins and related metabolites. Med Res Rev 1988;8:525-56
   PubMed Web of Science ®Google Scholar
• Kuzumaki T, Matsuda A, Wakamatsu K, et al. Eumelanin biosynthesis is regulated by coordinate expression of tyrosinase and tyrosinase-related protein-1 genes. Exp Cell Res 1993;207:33-40
   PubMedGoogle Scholar
• Park SH, Kim DS, Kim WG, et al. Terrein: a new melanogenesis inhibitor and its mechanism. Cell Mol Life Sci 2004;61:2878-85
   PubMed Web of Science ®Google Scholar
• Halaban R, Patton RS, Cheng E, et al. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem 2002;277:14821-8
   PubMed Web of Science ®Google Scholar
• Te-Sheng C. Natural melanogenesis inhibitors acting through the down-regulation of tyrosinase Activity. Materials 2012;5:1661-85
   Google Scholar
• Hodgkinson CA, Moore KJ, Nakayama A, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993;74:395-04
   PubMed Web of Science ®Google Scholar
• Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004;17:318-25
   PubMedGoogle Scholar
• Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000;14:1712-28
   PubMed Web of Science ®Google Scholar
• KEGG Pathway database. Available from: http://www.genome.jp/kegg/pathway.html [Last accessed 7 August 2012]
   Google Scholar
• Busca R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res 2000;13:60-9
   PubMedGoogle Scholar
• Pawelek J, Sansone M, Koch N, et al. Melanoma cells resistant to inhibition of growth by melanocyte stimulating hormone. Proc Natl Acad Sci USA 1975;72:951-5
   PubMedGoogle Scholar
• Saito H, Yasumoto K, Takeda K, et al. Microphthalmia-associated transcription factor in the wnt signaling pathway. Pigment Cell Res 2006;16:261-5
   Google Scholar
• Shibahara S, Takeda K, Yasumoto K, et al. Microphthalmia-associated transcription factor (MITF): multiplicity in structure, function, and regulation. J Invest Dermatol Symp Proc 2001;6:99-104
   PubMedGoogle Scholar
• Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003;22:3035-41
   PubMed Web of Science ®Google Scholar
• Ikeya M, Lee SM, Johnson JE, et al. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 1997;389:966-70
   PubMed Web of Science ®Google Scholar
• Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signaling pathway. Nature 1998;396:370-3
   PubMed Web of Science ®Google Scholar
• Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-305
   PubMed Web of Science ®Google Scholar
• Eastman Q, Grosschedl R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr Opin Cell Biol 1999;11:233-40
   PubMed Web of Science ®Google Scholar
• Widlund HR, Horstmann MA, Price ER, et al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002;158:1079-87
   PubMedGoogle Scholar
• Busca R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res 2000;13:60-9
   PubMedGoogle Scholar
• Englaro W, Bertolotto C, Busca R, et al. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem 1998;273:9966-70
   Google Scholar
• Jordan SA, Jackson IJ. MGF (KIT ligand) is a chemokinetic factor for melanoblast migration into hair follicles. Dev Biol 2000;225:424-36
   Google Scholar
• Tsukamoto K, Ueda M, Hearing VJ. Melanogenesis in murine melanocytes is suppressed by infection with the v-rasHa oncogene. Pigment Cell Res Suppl 1992;2:181-4
   Google Scholar
• Kim DS, Hwang ES, Lee JE, et al. Sphingosine-1-phosphate decreases melanin synthesis via sustained ERK activation and subsequent MITF degradation. J Cell Sci 2003;116:1699-706
   PubMed Web of Science ®Google Scholar
• Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998;391:298-301
   PubMed Web of Science ®Google Scholar
• Dermira (Canada), INC. (CA/US). Compounds and composition for modulating melanogenesis and pigmentation activities. WO052508A1;2013
   Google Scholar
• New York University, New York, NY (US). Indole alkaloid compounds as melanogenesis promoter and use thereof. US0302264 A1;2013
   Google Scholar
• L’oreal, Paris (FR). Use of cannabinoid compounds for stimulating melanogenesis. US0193349 A1;2014
   Google Scholar
• ELC Management LLC (US/US). Modulation of melanogenesis by modification of tyrosinase by palmitoylation. WO099609 A1;2014
   Google Scholar
• Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylation, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000;14:301-12
   PubMed Web of Science ®Google Scholar
• Rendon MI, Gaviria JI. Review of skin-lightening agents. Dermatol Surg 2005;31:886-9
   Web of Science ®Google Scholar
• Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 2006;3:541-50
   PubMedGoogle Scholar
• Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007;20:308-13
   PubMed Web of Science ®Google Scholar
• Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc 2008;13:20-4
   PubMedGoogle Scholar
• Kamakshi R. Fairness via formulations: a review of cosmetic skin-lightening ingredients. J Cosmet Sci 2012;63:43-54
   Google Scholar
• Solano F, Briganti S, Picardo M, et al. Hypopigmenting agents: an updated review onbiological, chemical and clinical aspects. Pigment Cell Res 2006;19:550-71
   PubMedGoogle Scholar
• Beradesca E, Cameli N, Primavera G, et al. Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg 2006;32:526-31
   Google Scholar
• Naish BS, Riley PA. Tyrosinase kinetics: failure of acceleration in oxidation of ring-blocked monohydric phenol substrate. Pigment Cell Res 1998;11:94-7
   Google Scholar
• Ando H, Kondoh H, Ichihashi M, et al. Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J Invest Dermatol 2007;127:751-61
   PubMed Web of Science ®Google Scholar
• Modiquest Therapeutics, Inc. Bothell, WA (US). Inhibitors of melanocyte tyrosinase as topical skin lighteners. US0023793 A1;2009
   Google Scholar
• Frenk E. Treatment of melasma with depigmenting agents. In: Melasma: new approaches to treatment. Martin Dunitz Ltd; London: 1995. pp 9-15
   Google Scholar
• Dooley TP, Gadwood RC, Kilgore K, et al. Development. of an in vitro primary screen for skin depigmentation and antimelanoma agents. Skin pharmcol 1994;7:188-200
   PubMedGoogle Scholar
• Curto EV, Kwong C, Hermersdörfer H, et al. Inhibitors of mammalian melanocytes tyrosinase: in vitro comparisons of alkyl esters of gentistic acid with other putative inhibitors. Biochem Pharmacol 1999;57:663-72
   PubMed Web of Science ®Google Scholar
• Galderma Research & Development, Biot, France. 4-Phenylimidazole-2-thione tyrosinase inhibitors and treatment of prevention of pigmentary disorders therewith. US0160401 A1;2010
   Google Scholar
• Galderma Research & Development, Biot, France. Novel 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof. US0144813 A1;2010
   Google Scholar
• Galderma Research & Development, Biot, France. Novel tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof. US0010049 A1;2010
   Google Scholar
• HEJ Research institute, Karachi (PK). Tyrosinase enzyme inhibitors from fungal hydroxylation of tibolone. US0136434 A1;2009
   Google Scholar
• Galderma Research & Development, Biot, France. 4-(azacycloalkyl)-benzene-1,3-diol derivatives as tyrosinase inhibitors and their synthesis and use thereof. US0323012 A1; 2012
   Google Scholar
• Merck Patent GMBH, Darmstadt (DE). Tyrosinase inhibitors. US0215594 A1;2010
   Google Scholar
• New York University, New York, NY (US). Inhibition of melanogenesis and melanoma metastasis with P-amino benzoic acid (PABA). US0323002 A1;2010
   Google Scholar
• Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001;98:9742-7
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001;20:6877
   PubMed Web of Science ®Google Scholar
• Elixir institute of regenerative medicine (US/US). Peptide tyrosinase inhibitors and use thereof. WO154959 A1;2012
   Google Scholar
• Ohguchi K, Tanaka T, Iliya I, et al. Gnetol as a potent tyrosinase inhibitor from genus Gnetum. Biosci Biotechnol Biochem 2003;67:663-5
   PubMed Web of Science ®Google Scholar
• Institute Curie, Paris Cedex (FR), Centre National De La Researche Scientifique, Paris (FR). Use of KIF13A and AP-1 inhibitors for inhibiting melanogenesis. US0321575 A1;2012
   Google Scholar
• Taipei Medical University, Taipei City (TW). Extracts and compounds for inhibiting tyrosinase activity. US0189826 A1;2010
   Google Scholar
• Avon Products, Inc., Suffern, NY (US). siRNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation. US0202458 A1;2009
   Google Scholar
• New York University School of Medicine [US/US]. Quinoline compounds as melanogenesis modifiers and uses thereof. US0298868 A1;2009
   Google Scholar
• a). New York University, New York, NY (US). Benzopyran compounds as melanogenesis modifiers and use thereof. US0196926 A1;2012.b). WO103493 A1;2012
   Google Scholar
• New York University School of Medicine [US/US]. Coumarin compounds as melanogenesis modifiers and uses thereof. US0220545 A1;2012
   Google Scholar
• Muhammed M. Melanogenesis inhibition-methods and compositions thereof. WO014515 A2;2014
   Google Scholar
• Ajou University Industry-Academic cooperation foundation [KR/KR]. The inhibitory melanogenesis by coffee oil extracted by supercritical CO2. WO069677 A1;2014
   Google Scholar
• (a) The Procter & Gamble Company. Methods for Inhibiting Tyrosinase Using an Extract of Laminaria Saccharina. US 2013/0022559 A1. (b). WO011906;2012
   Google Scholar
• Videira IF, Moura DF, Magina S, et al. Mechanisms regulating melanogenesis. An Bras Dermatol 2013;88:76-83
   PubMed Web of Science ®Google Scholar